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Francesco Dondi, Maria Morini, Riccardo Rinnovati, Alessandro Spadari and
Noemi Romagnoli
Department of Veterinary Medical Sciences, University of Bologna, Ozzano Dell’Emilia, Italy
Proteinase activated receptor 4 (PAR4) in the gastrointestinal tract is involved in the
regulation of inflammation and pain pathways. The aim of the present study was to
evaluate the distribution and expression of PAR4 in the jejunum of healthy horses and
in the pathologic tracts from horses undergoing surgery for herniation of the small
intestine through the epiploic foramen. Eight healthy horses (Group H) and eight horses
with epiploic hernia (Group EH) were included; the jejunum samples were collected
at the slaughter or intraoperatively after enterectomy, respectively. To evaluate PAR4
expression in sections of the jejunum, immunofluorescence, western blot and quantitative
polymerase chain reaction (qRT-PCR) were performed. Immunohistochemistry of PAR4 in
the jejunum of the healthy horses showed that receptors are predominantly expressed in
the immune cell population scattered throughout the lamina propria of the mucosa and in
the submucosa. Quantitative PCR data demonstrated that PAR4 mRNA was detectable
in all of the samples analyzed without any difference between the H and the EH groups,
however the PAR4 protein level was significantly lower in the jejunums of the EH horses.
In the Group EH horses, PAR4 immunoreactivity was mainly expressed in the mast cells
and was extensively distributed in the sierosa. In the lamina propria of mucosa of Group
EH, leukocytes were less abundant than in Group H. In this study, the distribution and
expression of PAR4 in the jejunums of the healthy horses and in those with spontaneous
occurring epiploic hernia was demonstrated.
Keywords: epiploic foramen hernia, equine, jejunum, mast cells, proteinase-activated receptor 4
INTRODUCTION
In horses, herniation of the small intestine through the epiploic foramen (epiploic hernia-EH) is
a common cause of strangulation of the small intestine and has been reported from 3.5 to 5% of
horses with colic undergoing surgery (4, 5). More frequently, compression within the foramen
or anatomical displacement cause vein occlusion with subsequent tissue congestion, oedema,
hemorrhagic infarction, and inflammation (6). Moreover, when artery compression develops,
ischemic lesions also appear (7). Tissue necrosis can advance up to one meter involving the afferent
and efferent intestinal loops not involved in the hernia (1).The surgical treatment of an EH consists
of reducing the herniation and resection of the abnormal intestinal tract (7). However, reperfusion
of the ischemic intestine might results in reperfusion injury characterized by the aggravation of the
aforementioned lesions (2, 8).
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Several studies in humans and in animal models have
investigated the role of proteinase activated receptors (PARs)
in the pathophysiology of intestinal diseases (9–12). Proteinase
activated receptors constitute a receptor subfamily belonging
to the largest group of G-protein coupled receptors (13–16).
In humans, PARs 1 to 4 have been identified throughout the
gastrointestinal tract where they are exposed to high levels of
proteinases, digestive proteinases, and those produced by enteric
pathogens, and are therefore relevant in the regulation of several
mechanisms (15, 17–19). In addition the expression of proteases
increases significantly during inflammatory processes (17). The
proteases interact with PARs by cleaving the extracellular N-
terminus portion; the tethered ligand that in this way is exposed
binds to a second extracellular ring of the receptor thereby
activating the receptor itself (9). Proteinase activated receptor
4 is activated by trypsin, cathepsin G and activated factor X
and is considered particularly involved in the regulation of
inflammation, nociception, sensitization, and pain pathways (20–
23). In humans, authors are investigating the role of PAR2 and
PAR4 in the pathogenesis of irritable bowel syndrome and in the
modulation of hypersensitivity associated with persistent tissue
inflammation (10, 12). The expression and distribution of PAR4
in the equine small intestine has not yet been investigated.
The aim of the present study was to evaluate the distribution
and expression of PAR4 in the jejunums of healthy horses and in
the ischemic tracts collected from horses undergoing surgery for
colic of the small intestine. Therefore, horses with herniation of
the small intestine through the epiploic foramen were considered
as model of inflammation and strangulating obstruction of the
small intestine.
To evaluate PAR4 expression in sections of the jejunum,




The study was approved by the Ethical Scientific Committee for
experimental animals of the University of Bologna (Prot. n 15-
IX/, 08/05/2012). Eight healthy horses (groupH) and eight horses
with EH (group EH) were included in the study.
In Group H, eight adult food-producing Standardbred horses
sent to slaughter were included. These horses were considered
healthy based on history, and physical and clinicopathological
examination, and on the basis of gross and histological
evaluations of the jejunum. There were five females and three
geldings of different breeds; their median age was 10.5 years
(range 2–20). In Group EH, eight adult sport Standarbred horses
(three females and five geldings) admitted to the Veterinary
teaching hospital (VTH) of the Department of Veterinary
Medical Sciences for colic syndrome and in which an exploratory
laparotomy confirmed a clinical diagnosis of herniation of the
small intestine through the epiploic foramen were included. All
patients underwent an enterectomy of the jejunum followed
Abbreviations: EH, Epiploic hernia; PAR, Proteinase activated receptor; PBS,
Phosphate buffered saline.
by anastomoses within 2-18 h from admission. At the end of
the surgery, horses with colic were followed by the VTH and
discharged within 7–10 days from admission.
Blood Sampling and Analysis
In the Group H horses, blood samples were collected from
the jugular vein at exsanguination. In the Group EH horses,
blood samples were collected within 30min from admission
from the jugular vein by venipuncture. Blood samples were
collected in K3EDTA, citrate and clot activator. In detail, a
complete blood count was carried out including: hematocrit
value, hemoglobin concentration, erythrocyte indices, platelet
count, and white blood cells and differential white blood cells
counts. The chemical profile included aspartate transaminase,
lactate dehydrogenase, creatine kinase, creatinine, urea, glucose,
lactate, total bilirubin, γ-glutamyl transferase, total protein,
total calcium, phosphorus, sodium, potassium, and chloride.
The coagulation profile included D-dimers and antithrombin.
The acute-phase protein profile included serum amyloid A,
haptoglobin, ferritin, fibrinogen, total iron, transferrin (such
as total iron binding capacity), and albumin. The samples
collected were processed and analyzed within one hour or
stored at −80◦C. The blood analysis were carried out using
an automated hematology system (ADVIA 2120, Siemens
Healthcare Diagnostics, Tarrytown NY, USA) and an automated
chemical analyzer (AU 400, Olympus/Beckman Coulter, Brea
CA, USA).
Sampling and Morphological Evaluations
In the group H horses, samples of the jejunum were collected at
the evisceration phase of the slaughter. At the time of collection,
samples were examined internally and externally to exclude gross
intestinal lesions. In the group EH horses, the abnormal tract of
the jejunum was resected intraoperatively and a jejuno-jejunal
or jejuno-ileal anastomosis was performed by an experienced
surgeon. The ischemic intestinal tract removed was used for
research purposes with the informed consent of the owners. All
the samples collected for the analysis were obtained in the center
of the abnormal removed intestine.
After collection, a part of the jejunum was dissected and
washed with phosphate buffered saline (PBS) (Gibco-Invitrogen,
Paisley, UK). The intestinal mucosa was then scraped with two
glass slides; the samples were frozen in liquid nitrogen and stored
at −80◦C until RNA and protein extraction were carried out. In
addition, full thickness bioptic samples from the jejunum were
carried out, rinsed in PBS and then immediately stored in 10%
neutral buffered formalin and 4% paraformaldehyde.
Histological evaluations were carried out on samples fixed
in 10% neutral buffered formalin, embedded in paraffin within
24–48 h, cut into 5µm thick sections and stained with
hematoxylin and eosin. For group H, the histological samples
were also evaluated according to an inflammation score using
a semiquantitative estimation of the inflammatory cells in the
mucosa and submucosa, as described by Packer et al. (24).
Only those horses in which the intestinal specimens were within
the normal range were included in the study. In addition, for
samples of both groups, tissue viability was determined based on
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the morphological changes present in the tissue sections using
light microscopy and was based on a scoring system previously
described by Van Hoogmoed et al. (25).
Immunohistochemistry Experiments
In both groups, samples for immunohistochemical evaluation
were prepared as previously described (26) to obtain 14–
15µm thick cryostat serial longitudinal sections, which were
mounted on polylysine-coated slides and stored at −80◦C until
immunohistochemical evaluations were carried out. The sections
were then rehydrated three times with PBS (0.02M, pH 7.4)
before beginning the immunostaining. To block non-specific
binding, the sections were incubated in a solution containing
10% normal donkey serum (Colorado Serum Co, Denver, CO,
USA) and 0.5% Triton X-100 (Merck, Darmstadt, Germany) in
PBS for an hour at room temperature in a humid chamber.
An hour later the sections were incubated in primary antibody
goat anti-PAR4 (1:100, Santa Cruz Biotechnology Cat# sc-8464,
RRID:AB_653835) diluted in antibody diluent (1.8% NaCl in
0.01M sodium phosphate buffer containing 0.1% sodium azide),
1% normal donkey serum and 0.5% Triton for 24 h at room
temperature in an humid chamber. The day after, the sections
were washed with PBS three times every 10min and incubated
in a solution containing a secondary antibody donkey anti-goat
(1:400, Alexa Fluor 594, Thermo Fisher Scientific, Waltham,MA,
USA, Cat# A-11058, RRID:AB_2534105), 1% normal donkey
serum, 0.5% Triton diluted in PBS in humid chamber. Finally,
the slides were washed three times with PBS and were then cover
slipped with buffered glycerol (pH 8.6).
Thereafter double immunohistochemistry evaluations were
performed adding different primary and secondary antibodies
to the solution previously described. The sections used for mast
cells assessments were incubated for 24 h at room temperature
with a primary antibody solution containing the antibody
rabbit anti-tryptase (1:80 Cloud clone corp, Huston, TX, USA,
PAB07Ca01). These sections were then washed in PBS (three
times for ten minutes each) and then incubated with a secondary
antibody solution containing the antibody donkey anti-rabbit
(1:200, Jackson ImmunoResearch Labs Inc., West Grove, PA,
USA; Cat# 711-095-152, RRID:AB_2315776). The slides were
then washed in PBS (three times for ten minutes each) and
finally coverslipped. The section used for lymphocytes T and B
assessment were incubated for 24 h at room temperature with
a primary antibody solution containing the antibody mouse
anti-CD3 (1:100; Sigma-Aldrich, Saint Luis, MO, USA, Cat#
C7930, RRID:AB_259074) or mouse anti-CD79 (1:100 Abcam,
Cambridge, UK, Cat# ab3121, RRID:AB_303528) respectively.
The sections were then washed in PBS (three times for ten
minutes each) and then incubated with a secondary antibody
solution containing the antibody donkey anti-mouse (1:200,
Jackson ImmunoResearch Labs Inc., West Grove, PA, USA,
Cat# 715-095-150, RRID:AB_2340792). The slides were then
washed in PBS (three times for ten minutes each) and finally
cover slipped.
An average of 10 sections were evaluated for each horse.
The immunofluorescence sections were observed using a Nikon
H550L (Nikon instrument, Japan) equipped with a TRITC filter
for Alexa 594 (EX 540/25; DM 565; BA 605-655) and a FITC
filter for Alexa 488 (Ex 465–495; DM 505; BA 515–555). The
images were recorded using a NikonQi1Mc photocamera (Nikon
instruments, Japan) and Nikon Elements Version 4.10 software;
the images were finally corrected for contrast and brightness
in order to reproduce the appearance observed through the
microscope, using Adobe Photoshop CS3 Extended 10.0 software
(Adobe systems, San Jose, CA, USA).
RNA Isolation and Quantitative Real Time
PCR (qRT-PCR) for PAR4
The RNA extraction was performed on samples collected from
each horse from the group H (n = 8) and the group EH (n = 8);
RNA extraction and qPCR analysis were essentially carried out
as reported by a previous study (26). Briefly, samples of scraped
jejunum mucosa were pulverized using a mortar and pestle and
liquid nitrogen; 25mg of each sample were then lysed in Tissue
Lyser TL (50Hz for 5min, 2 beads diameter 2mm, QIAGEN,
Hilden, Germany). The total RNA extraction was carried
out using the NucleoSpin RNA II (Macherey Nagel, Duren,
Germany) instructions. The RNA was spectrophotometrically
quantified (A260 nm), and its quality was determined by gel
electrophoresis on 1% agarose. Subsequently, 1 µg of RNA was
reverse-transcribed to cDNAusing an iScript cDNA Synthesis Kit
(Bio-Rad Laboratories Inc., Hercules, CA, USA) in a final volume
of 20 µl. Real-time quantitative PCR was carried out using a
CFX 96 Real Time System (Bio-RAD Laboratories Inc.) and iTaq
Universal SYBR Green Supermix (Bio-RAD Laboratories Inc.).
All samples were analyzed in duplicate (10 µl/well).
The PAR4 and reference genes (GAPDH; HPRT and β-
Actin) primer sequences, expected PCR product lengths and
the accession numbers in the National Center of Biotechnology
Information (NCBI) database are shown in Table 1.
The expression level of the PAR4 gene was determined
using the 2−11Ct method (27) in which 1Ct = (Ct PAR4-Ct
mean ref.genes) and 11Ct= 1Ct EH−group-1Ct H−group.
PAR4 Western Blotting
One sample collected from each horse of the group H (n= 8) and
of the group EH (n= 8) was used for the western blot analysis.
Fifty mg of pulverized jejunum mucosa were lysed with
sodium dodecyl sulfate solution (Tris-HCl 50mM pH 6.8;
sodium dodecyl sulfate 2%; glycerol 5%; 500 µl) supplemented
with a protease inhibitor cocktail (P8340, Sigma-Aldrich, Co,
St. Louis, MO, USA) in Tissue Lyser TL (50Hz for 2min,
3 beads diameter 2mm). The protein content of the samples
was determined using a Protein Assay Kit (TP0300, Sigma-
Aldrich, Co, St. Louis, MO, USA). Aliquots containing 20 µg
of protein were separated using Bolt 4–12% bis-Tris Plus (Life
Technologies Ltd, Paisley, UK) for 55min at 165V. The proteins
were then electrophoretically transferred onto a nitrocellulose
membrane using the Turbo Blot System (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The blots were washed in PBS, and
protein transfer was checked using 0.2% Ponceau Red staining.
Non-specific binding on nitrocellulose membranes was blocked
with 5% milk in PBS-T20 (phosphate buffer saline-0.1% Tween-
20) for 1 h at room temperature. The membranes were then
Frontiers in Veterinary Science | www.frontiersin.org 3 March 2020 | Volume 7 | Article 158
Lambertini et al. PAR4 in the Equine Gut
TABLE 1 | The proteinase activated receptor 4 (PAR4) and references gene (GAPDH; HPRT; β-Actin) forward and reverse primer sequences, expected PCR product
lengths and accession number (AN) in the NCBI (National Center of Biotechnology Information) database.
Gene Sequence (5′-3′) PCR length (bp) AN References
PAR-4 For: ATGCGATCCTGCTGCTGTG 112 XM_001499653 Present study
Rev.: GCGTCACTGTCACCGTCC
GAPDH For.: TGGTGAAGGTCGGAGTAAAC 120 NM_001163856 Zannoni et al. (26)
Rev.: TGTAGTTGAGGTCAATGAAGGG
HPRT For.: GCGTCGTGATTAGTGATGATGAAC 179 AY372182 Zannoni et al. (26)
Rev.: ACAGAGTGCTACAATGTGATGGC
β-Actin For.: ATCGTGCGTGACATCAAGGA 169 AF035774.1 Zannoni et al. (26)
Rev.: AGGAAGGAGGGCTGGAAGAG
incubated overnight at 4◦C with a 1:200 dilution of primary
antibody goat anti-PAR4 (sc-8464, Santa Cruz Biotechnology,
Dallas, TX, USA) in Tris Buffered Saline-T20 (TBS-T20 20mM
Tris-HCl, pH 7.4, 500mM NaCl, 0.1% T-20). After several
washings with PBS-T20, the membranes were incubated with
the secondary donkey anti-goat IgG-HRP antibody (sc-2020,
Santa Cruz Biotechnology Cat# sc-2020, RRID:AB_631728,
1:7000 dilution in TBS-T20, 1 h at RT). The Western blots
were developed using chemiluminescent substrate (Clarity ECL
Western Blot Substrate, Bio-Rad Laboratories Inc., Hercules,
CA, USA) according to the manufacturer’s instructions. The
intensity of the luminescent signal of the resultant bands was
acquired using the Chemi Doc Instrument (Bio-Rad Laboratories
Inc., Hercules, CA, USA) with LabImage Software (Bio-Rad
Laboratories Inc, Hercules, CA, USA).
In order to normalize the PAR4 data on the reference protein,
the membranes were washed for 5min in water, then for 5min
in 0.2M NaOH and then washed again in water and reprobed
for the reference α-tubulin (1:500; cod.TU-01 Thermo Scientific
Waltham, MA, USA). The relative PAR4 protein content was
normalized on the mean value of the reference protein (α-
tubulin) and was expressed as arbitrary units.
Statistical Analysis
Descriptive statistic was used to evaluate the clinicopathological
data, and the reference intervals of our laboratory were used for
comparison. The PAR4 protein and mRNA in the jejunum were
compared between the H and the EH groups using a student t-
test. p < 0.05 was considered statistically significant. The protein
and mRNA analyses were carried out using GraphPad Prism




In group H horses the clinicopathological results were within
the normal reference range. In group EH horses an increase
in Serum amyloid A (median 149µg/mL; reference range: 1–
10µg/mL), creatinine (median 2.15 mg/dL; reference range:
0.90–1.50 mg/dL) and d-dimer (median 2.90µg/mL; reference
range: 0.20–0.48µg/mL) concentrations were observed. These
results have already been published in a previous paper (28). At
histological evaluation of the samples collected from the horses
in group H, the median score was 2 (range 0–3). Twenty four
samples were collected from the horses in group EH; in all
of them the median score was 12 (range 6–40). In terms of
hemorrhage and edema score (25) in this latter group, 14 samples
had lesions of mild severity, while 10 samples had extensive
disruption of structural integrity .
In the samples from group H, the quantitative data regarding
the inflammatory cell populations was within the normal range
as previously defined by Packer et al. (24).
Immunohistochemistry
Proteinase activated receptor 4 immunohistochemistry in the
jejunums of the healthy horses showed a weak receptor
distribution, mainly in immune cell population, especially
lymphocytes (Figure 1). These cells were predominant in the
lamina propria of the mucosa and in the submucosa. In
the submucosa, lymphocytes were observed only in a diffuse
form. Proteinase activated receptor 4 immunoreactivity was not
observed in the enterocytes and intestinal glands; in addition,
the smooth muscle cells were negative with the exception of a
few elements having weak immunoreactivity. In the superficial
epithelium, lymphocytes with weak staining were observed.
Some mast cells immunostained for tryptase were located in the
submucosa (Figures 2A–C) and in the serosa (Figures 2D–F).
In group-EH horses, lymphocytes of the lamina propria of
mucosa exhibited an intensity of immunofluorescence slightly
lower than in group H. In the submuscosa and superficial
epithelium some weakly-immunostained lymphocytes could be
observed. In this group, PAR4 immunoreactivity was mainly
expressed in the mast cells, immunostained for tryptase that
were extensively distributed in the serosa (Figures 2G–L). The
intensity of the immunofluorescence of the mast cells was
similar in the two groups. Immunoreactivity was not observed
in the submucosal and myenteric plexi either in Group H or in
Group EH.
Quantitative Real-time PCR for PAR4 in the
Equine Jejunum
Quantitative PCR data demonstrated that PAR4 mRNA was
detectable in all of the samples analyzed.
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FIGURE 1 | Lymphocytes immunoreactive for the PAR4 (PAR4-IR) in the lamina propria of the horse jejunum of group H (A–F) and group EH (G–L). (A–C) and (G–I):
Anti-CD79 in green (LB), PAR4-IR in red (P) and co-localization of PAR4 and CD79 in B lymphocytes in yellow (LB+P). (D–F) and (J–L): Anti-CD3 in green (LT),
PAR4-IR in red (P) and co-localization of PAR4 and CD3 in T lymphocytes in yellow (LT+P). Arrowheads indicate double immunolabeled lymphocytes. Scale bar =
20µm in L (applied to A–L).
No significant statistical difference of its expression in the
jejunum tracts was observed between the groups EH (2−11Ct =
0.49) andH (2−11Ct = 1). The range of relative expression (lower
and upper range), represented as error bars, was: 0.574–1.348 for
H group and 0.365–1.41 for EH group (Figure 3).
PAR4 Western Blotting in the Equine
Jejunum
Under denaturing gel electrophoresis conditions (SDS–PAGE),
western blots of the mucosa of the equine jejunum tracts
showed a clear band of the expected molecular weight for
PAR4 (∼38 kDa) (Figures 4A,B). The PAR4 protein level was
statistically lower in the jejunum tracts of the group EH
(p < 0.05) (Figure 4C).
DISCUSSION
In the present study, the distribution and expression of PAR4 in
the jejunum of healthy horses and in those with spontaneous
occurring epiploic hernia has been demonstrated for the
first time.
The expression and distribution of PAR4 has been investigated
in humans and in mice (10, 12, 17, 19, 20, 22). In details, PAR4
mRNA expression has been identified in the small intestine and in
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FIGURE 2 | Mast cells immunoreactive for the PAR4 can be occasionally observed in the submucosa (A–C, G–I) and in the sierosa (D–F, J–L) in horse jejunum of
group H (A–F) and group EH (G–L). Tryptase in green (M), PAR4-IR in red (P) and co-localization of PAR4 with tryptase in yellow (M+P). Arrowheads indicate double
immunolabeled mast cells. Scale bar = 30µm in L (applied to A–L).
the colon. In the colon the immunohistochemistry demonstrated
the expression of PAR4 at the epithelium surface and crypts, in
the submucosa and in the majority of mast cells (10, 12, 17).
In the present study, immunoreactivity was not observed in the
enterocytes and the submucosal cells, but mainly in the immune
cell population identified as mast cells and B and T lymphocytes.
The expression of PAR4 in B lymphocytes has already been
described in the human liver but authors did not find PAR4
mRNA in human circulating lymphocytes (29, 30).
The expression of PAR4 in mast cells is in accordance with
previous studies in humans (10, 12). In particular, in human
patients the inflammatory bowel disease resulted in a reduced
expression of PAR4 in the colonic mast cells supporting its role
in the modulation of visceral nociception (10, 12). Conversely,
the results of the present study showed that the expression of
PAR4 on mast cells in the jejunum did not change between
healthy horses and those with epiploic hernia. However, we
could not exclude that the lack of difference in the expression
of PAR4 on these cells between the two groups is associated
with the acute onset of the inflammatory process affecting the
horses with epiploic hernia. The mast cells, in the peripheral
tissues, modulate the nociceptive pathways, especially those
of inflammatory origin. In fact, by means of mediators and
cytokines release (tryptase and interleukin 1β) they activate other
immune cells (neutrophils, macrophages and T cells) and amplify
the inflammatory response (3, 31, 32). The mast cells in the
intestinal tract seem to be particularly involved in the regulation
of visceral hypersensitivity through PAR4 (3, 33, 34). In fact,
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FIGURE 3 | Quantitative Real time PCR for PAR4 in the equine jejunum tracts.
The gene expression level of PAR4 in the EH group (n = 8) was calculated in
relation to the samples isolated from the healthy group (H, n = 8), as fold of
change (2 −11Ct method in which 1Ct = Ct PAR4-Ct mean ref.genes and 11Ct =
1Ct EH−group-1Ct H−group). Error bars represent the range of relative
expression of PAR4 in each group. No statistically significant differences in
gene expression were observed (student t-test, p < 0.05).
FIGURE 4 | Proteinase activated receptor 4 protein expression in the jejunum
intestinal tracts of equines with a diagnosis of epiploic hernia (EH, n = 8) and
in healthy subjects (H, n = 8). Representative image of Western blots of the
PAR4 protein (A) and the reference protein α-tubulin (B) in the intestinal tracts
of equines. In lane 1, the molecular weight marker (kDa). Western blot analysis
of PAR4 in the jejunum intestinal tracts isolated from the H and the EH groups
(C). A significant reduction in PAR4 expression was observed in the EH group)
(student t-test, p < 0.05). AU = Arbitrary Unit. Data represent the mean ± SD
of 8 biological replicates for each group. *represents a p < 0.05.
in-vitro or in-vivo activation of PAR4 on mast cells resulted in a
suppression of mRNA and protein levels of tryptase and 13 types
of proinflammatory cytokines (3, 35). On the contrary the role
of the PAR4 in lymphocytes is still to be clarified, however it does
not seem to be involved in the modulation of nociception. In fact,
Annaházi et al. (20) observed that in mice a functional deficiency
of B and T cells did not affect the antinociceptive effect induced
by the administration of a PAR4 activating peptide.
Based on these results, several authors are further investigating
the involvement of PAR4 in visceral nociception and pain (3, 20–
22). Augé and colleagues found that in mice, the intracolonic
administration of a synthetic PAR4 activating peptide decreased
the nociceptive response induced by visceral stimulation and
inhibited the colonic hypersensitivity induced by the previous
activation of the PAR2 (22). The same authors found also that
PAR4-deficient mice showed enhanced pain behaviors (licking of
abdomen, stretching and abdominal retractions) in response to
colorectal stimuli as compared with wild type animals (22). In
addition, the presence of PAR4 has been demonstrated in the
dorsal root ganglia neurons where it reduces their excitability
(36). These findings confirm the role of PAR4 not only in
the modulation of nociception but also in the regulation of
pain pathways.
A simultaneous activation of both PAR2 and PAR4 in the
jejunum of horses with epiploic hernia and their involvement in
the modulation of the inflammatory process associated with this
pathological condition can’t be excluded. In the equine bowel,
the PAR2 expression has already been described either in healthy
animals or in those with spontaneous occurring EH (26, 28).
The results of these previous studies support an activation of
the PAR2 during the ischemic process associated with intestinal
herniation (28). Herein, the lower protein level for PAR4 found
in the jejunums of horses with epiploic hernias, as compared with
samples collected from healthy horses, supports the activation
of PAR4 (37, 38). In fact, the activation of PARs by proteinases,
is characterized by an irreversible proteolytic cleavage of the N-
terminal domain of the receptor determining a conformational
change of the receptors itself which is then internalized to
reach intracellular effectors (37). After internalization PARs are
degraded by lysosomes or recycled by endosomes (37). The
degradation of the receptor can explain the decreased protein
level observed in our study.
Proteinase activated receptors have been described also in the
enteric nervous system where they are activated by proteinases,
and they induce excitatory neuronal responses (18, 39). In
the small intestine of the guinea pig, authors have found that
submucosal plexus neurons express PAR2 and that a large
proportion of myenteric neurons express PAR1 and PAR2 (40,
41). However, Mueller et al. (18) also found that stimulation with
a PAR4 selective peptide induced a spike discharge in human
and guinea pig submucosal neurons, even if the response was
weaker and involved fewer neurons when compared with that
obtained after the application of the PAR1 selective peptide.
In horses, the submucosal plexus neurons and the myenteric
plexus neurons expressed PAR2 (26, 28) but, in the present
study, immunostaining for PAR4 was not observed in these
cells. Therefore, based on the lack of expression of PAR4 in the
enteric nervous system’s neurons, it can be hypothesized that, in
equine jejunums, this receptor is not involved in the regulation
of neurotransmission in both healthy horses and in horses
with epiploic hernia. Instead, PAR2 could be involved in the
alteration of neurotransmission and intestinal motility during an
inflammatory process as previously described in animal models
(42). However, to date, there are no data concerning the role of
PAR activation in the enteric nervous system in horses.
The increase in the SAA and plasmatic D-dimer and
creatinine concentrations above the reference range are in
accordance with previous studies in colic horses (43–46). In
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fact, the intestinal inflammatory process results in an increased
concentration of acute phase protein like SAA (44, 47). In details,
the increase of SAA concentration better correlates with the
presence of inflammatory lesions compared with strangulating
obstruction and in a previous study only the 21% of horses
with pathologies involving the small intestine had an increase of
SAA concentration above the reference range (44). In addition,
disseminated intravascular coagulation is a complication related
with acute gastrointestinal tract disease in horses. Increased
plasma D-Dimer concentration and creatinine concentration
have been previously reported in colic horses with coagulation
disorders as marker of coagulopathies and subsequent organ
damage respectively (43, 45, 48). However, clinical disseminated
intravascular coagulation was not observed in the patients of the
present study. The relationship between PAR4 expression and
SAAwas not evaluated. Further studies are needed to evaluate the
application of the evaluation of PAR4 expression in association
with SAA as a diagnostic and prognostic tool in horses with
epiploic hernia.
In conclusion, these preliminary results support PAR4
expression in the equine jejunum and its potential activation
during small intestinal herniation though the epiploic foramen.
On the basis of previous studies, the local administration of the
PAR4 activating peptide could be taken into consideration as a
novel therapeutic approach for the treatment of inflammation
and pain in horses with gastrointestinal disorders. In addition,
as previously demonstrated in rodents, in equine species PAR4
activation might be involved in the modulation of visceral
hypersensitivity associated with the PAR2 activation. However,
the expression of PAR4 in the other intestinal tracts of the horse
has still to be clarified and additional studies are needed to clearly
define the role of PAR4 in the equine intestine.
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